Holen Sie sich die Stockscreener-App
0.3427
5.71%
-0.0232
Aethlon Medical Inc Aktie (AEMD) Neueste Nachrichten
Virtu Financial LLC Buys Shares of 94,173 Aethlon Medical, Inc. (NASDAQ:AEMD) - Defense World
Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com - Defense World
Aethlon Medical at Emerging Growth Virtual Conference: Oncology Focus and Financial Strategy - Investing.com
Aethlon Medical (NASDAQ:AEMD) & Nephros (NASDAQ:NEPH) Head to Head Comparison - Defense World
Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com - Defense World
Aethlon Medical issues new warrants, modifies rights By Investing.com - Investing.com Australia
Aethlon Medical issues new warrants, modifies rights - Investing.com
Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Drops By 52.0% - Defense World
Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aethlon Medical’s (AEMD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Buy Rating for Aethlon Medical Driven by Hemopurifier’s Potential in Organ Transplantation and Projected Growth - TipRanks
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal - Investorideas.com newswire
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal - Yahoo Finance
AEMDAethlon Medical Latest Stock News & Market Updates - Stock Titan
Aethlon Medical, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Aethlon Medical, Inc. to Host Earnings Call - ACCESS Newswire
HC Wainwright Boosts Earnings Estimates for Aethlon Medical - Defense World
Aethlon Medical (NASDAQ:AEMD) Receives “Buy” Rating from HC Wainwright - Defense World
Aethlon Medical (NASDAQ:AEMD) Raised to Sell at StockNews.com - Defense World
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 21.3% in January - Defense World
Aethlon Medical strengthens oncology trial with protocol updates and cost reductions - MSN
Aethlon Medical IncThe company expects to conduct a capital raise that - Smartkarma
Aethlon’s Earnings Call: Trials and Cost Strategies - TipRanks
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2025 Earnings Call Transcript - Insider Monkey
Live Investor Update: Aethlon Medical Unveils Latest Cancer Treatment ProgressCEO Takes Questions - StockTitan
Aethlon Medical operating expenses drop 50% in Q3 2024 - Medical Buyer
Earnings call transcript: Aethlon Medical Q4 2024 sees cost cuts, stock rises - Investing.com Nigeria
Aethlon Medical Reports Q3 Results and Corporate Update - TipRanks
Aethlon Medical Inc. (AEMD) reports earnings - Quartz
Aethlon Medical Achieves Milestone in Oncology Trials - TipRanks
Aethlon's Hemopurifier Cancer Trial Milestone Achieved as Q3 Expenses Drop 50% - StockTitan
Head-To-Head Review: NeuroPace (NASDAQ:NPCE) vs. Aethlon Medical (NASDAQ:AEMD) - Defense World
Critical Analysis: Aethlon Medical (NASDAQ:AEMD) and Becton, Dickinson and Company (NYSE:BDX) - Defense World
Stock Of Aethlon Medical Inc (NASDAQ: AEMD) Dropped By -13.43 Percent Over The Past Month, Is There Room For Downside? – Marketing Sentinel - Marketing Sentinel
Aethlon Medical Inc (AEMD) Stock: A Value Analysis - The News Heater
Aethlon Medical Inc (AEMD) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Aethlon Medical Q3 Earnings Preview: Cancer & Infectious Disease Pipeline Takes Center Stage - StockTitan
Exosome Diagnostics & Therapeutics Market to Grow by USD 1.01 Billion (2025-2029) with Rising Research in Exosome Therapeutics Boosting the Market, Report on How AI is Driving Market TransformationTechnavio - The Malaysian Reserve
Aethlon Medical (NASDAQ:AEMD) Earns Buy Rating from HC Wainwright - Defense World
Aethlon Medical treats first subject with Hemopurifier device in Australia - Medical Device Network
Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update - Investorideas.com newswire
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial - Investorideas.com newswire
Aethlon announces treatment of first patient with Hemopurifier in Australia - TipRanks
Revolutionary Blood Filter Could Boost Cancer Immunotherapy Success Rates by 60% - StockTitan
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 201.5% in January - Defense World
1.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):